| 2024/11/08 22:00:00 | |
|---|---|
| Price | |
| 173.04 USD | |
| Difference | -0.51% (-0.88) |
General attributes
| ISIN | US09062X1037 |
| Symbol | BIIB |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 23,474 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 171.74 USD (200) |
| Ask (Ask size) | 174.00 USD (100) |
| Open | 173.58 USD |
| High | 175.20 USD |
| Low | 171.57 USD |
| Close (prev. day) | 173.92 USD |
| VWAP | 172.688352 USD |
| Volume (pcs) | 1,581,624 |
| Trading volume | 273,073,779.74 |
| Number of trades | 34,424 |
| Last size | - |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: BIOGEN IDEC INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/11/05 |
|
Global Equity Ratings |
|
| 2024/10/29 |
|
Global Equity Ratings |
|
| 2024/10/22 |
|
Global Equity Ratings |
|
| 2024/10/08 |
|
Global Strategy 4Q 2024 |
|
| 2024/09/27 |
|
Global Equity Ratings |
|
| 2024/11/08 22:00:00 | |
|---|---|
| Price | |
| 173.04 USD | |
| Difference | -0.51% (-0.88) |
General attributes
| ISIN | US09062X1037 |
| Symbol | BIIB |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 23,474 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 171.74 USD (200) |
| Ask (Ask size) | 174.00 USD (100) |
| Open | 173.58 USD |
| High | 175.20 USD |
| Low | 171.57 USD |
| Close (prev. day) | 173.92 USD |
| VWAP | 172.688352 USD |
| Volume (pcs) | 1,581,624 |
| Trading volume | 273,073,779.74 |
| Number of trades | 34,424 |
| Last size | - |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -20.56% | -29.19% | -37.59% |
| Perf (abs.) | -45.00 | -71.69 | -104.76 |
| Beta | 0.51 | 0.65 | 0.80 |
| Volatility | 26.01 | 26.08 | 33.88 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 174.51 USD (1,937,927) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 184.47 USD (1,406,208) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 203.43 USD (1,145,291) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 218.75 USD (1,144,869) |
| YTD High | date | 268.30 USD (2024/01/03) |
| YTD Low | date | 170.71 USD (2024/11/04) |
| 52 Weeks High | date | 268.30 USD (2024/01/03) |
| 52 Weeks Low | date | 170.71 USD (2024/11/04) |
All listings for BIOGEN IDEC INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/11/08 | 17:35 | 160.50 EUR | 0.01 | 10 |
| Vienna Stock Exchange | 2024/11/08 | 17:32 | 160.40 EUR | 0.00 | 5 |
| Tradegate | 2024/11/08 | 22:26 | 161.45 EUR | 0.17 | 10 |
| Stuttgart | 2024/11/08 | 21:31 | 161.05 EUR | 0.00 | 8 |
| SIX Swiss Exchange | 2022/09/28 | 17:36 | 222.00 CHF | 0.00 | 1 |
| Nasdaq | 2024/11/08 | 22:00 | 173.04 USD | 273.07 | 34,424 |
| Munich | 2024/11/08 | 17:25 | 160.70 EUR | 0.00 | 3 |
| London Stock Exchange | 2024/10/25 | 16:27 | 185.04 USD | 0.01 | 1 |
| Hanover | 2024/11/08 | 17:25 | 160.70 EUR | 0.00 | 4 |
| Hamburg | 2024/11/08 | 17:25 | 160.70 EUR | 0.00 | 4 |
| Frankfurt | 2024/11/08 | 15:49 | 160.30 EUR | 0.00 | 1 |
| Euronext Milan MTF Trading After Hours | 2024/10/28 | 18:53 | 171.90 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/11/08 | 17:44 | 160.45 EUR | 0.00 | 1 |
| Duesseldorf | 2024/11/08 | 19:30 | 160.40 EUR | 0.00 | 7 |
| Berlin | 2024/11/08 | 21:48 | 160.95 EUR | 0.00 | 18 |
Company Logo
Contact Details
| BIOGEN INC. |
| - - |
| 225 Binney Street - 02142 Cambridge |
| Telefon: +1-617-679-2000 |
| Fax: + |
| E-mail: info@biogen.com |
PDF Downloads
| Company report: BIOGEN IDEC INC. | |
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. |
Members of Management Board
| Caroline Dorsa | Chairman of Board of Directors |
| Eric Rowinsky | Member of Board of Directors |
| Lloyd Minor | Member of Board of Directors |
| Maria Freire | Member of Board of Directors |
| Menelas Pangalos | Member of Board of Directors |
| Stephen Sherwin | Member of Board of Directors |
| Jesus Mantas | Member of Board of Directors |
| Monish Patolawala | Member of Board of Directors |
| Susan Langer | Member of Board of Directors |
| William Hawkins | Member of Board of Directors |
| Chris Viehbacher | Chairman of Managing Board |
| Ginger Gregory | Member of Executive Committee |
| Michael McDonnell | Member of Executive Committee |
| Nicole Murphy | Member of Executive Committee |
| Priya Singhal | Member of Executive Committee |
| Rachid Izzar | Member of Executive Committee |
| Susan H. Alexander | Member of Executive Committee |